AZITHROMYCIN IMPURITY C(CAS: 620169-47-3)

Azithromycin C (CAS: 620169-47-3) falls under regulatory guidelines such as the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH regulations in the EU, and FDA/EPA requirements in the United States. It is important to comply with these guidelines for proper handling, storage, and disposal of the compound.

There are alternatives to Azithromycin C in synthesis, such as other macrolide antibiotics like clarithromycin and erythromycin. Common alternative reagents include different starting materials and catalysts that can reduce the synthesis time and improve yield. However, each alternative may have its own set of regulatory and environmental considerations.

The market for Azithromycin C (CAS: 620169-47-3) is driven by its usage in treating respiratory and other bacterial infections. Research trends include developing more potent and less resistant forms of macrolides. The trend also involves exploring the compound's potential in combination therapies and new delivery systems to enhance efficacy and reduce side effects.

Waste containing Azithromycin C (CAS: 620169-47-3) should be collected in sealed containers and disposed of according to local waste management regulations. Incineration or professional waste disposal services are recommended to ensure proper degradation and minimize environmental impact. Proper waste handling is crucial to prevent contamination and protect the environment.